Logo image of RNAZ

TRANSCODE THERAPEUTICS INC (RNAZ) Stock News

NASDAQ:RNAZ - Nasdaq - US89357L4023 - Common Stock - Currency: USD

0.3418  -0.01 (-2.4%)

After market: 0.3318 -0.01 (-2.93%)

RNAZ Latest News, Press Relases and Analysis

News Image
5 days ago - Chartmill

These stocks that are showing activity before the opening bell on Monday.

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Mentions: PTCT APVO NCNA AGMH ...

News Image
7 days ago - Chartmill

Wondering what's happening in today's after-hours session?

After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Mentions: CEP CMLS MAN MRIN ...

News Image
2 days ago - TransCode Therapeutics, Inc.

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...

News Image
4 days ago - TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating...

News Image
5 days ago - Benzinga

US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert

U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Futures of benchmark indices were lower in premarket.

Mentions: BON SPY HSIC CMI ...

News Image
7 days ago - TransCode Therapeutics, Inc.

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating...

News Image
8 days ago - Stocktwits

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside

TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns.

News Image
8 days ago - Chartmill

Here are the top movers in Thursday's session.

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Mentions: TRVG NAOV LUNG ARVN ...

News Image
8 days ago - Chartmill

These stocks are making the most noise in today's session.

These stocks are making the most noise in today's session. Stay tuned for the latest updates!

Mentions: F PLUG NVDA TSLA ...

News Image
8 days ago - Chartmill

Top stock movements in today's session.

Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top gainers and losers in today's session.

Mentions: CEP OIS TWI CMLS ...

News Image
8 days ago - Chartmill

The market is filled with gapping stocks in Thursday's session.

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Mentions: SRI TWI CNMD CMLS ...

News Image
9 days ago - TransCode Therapeutics, Inc.

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...

News Image
18 days ago - TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating...

News Image
21 days ago - Zacks Investment Research

All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy

TransCode Therapeutics (RNAZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

News Image
a month ago - TransCode Therapeutics, Inc.

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...

News Image
2 months ago - TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

/PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating...

News Image
2 months ago - TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

/PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics,...